About Mereo BioPharma Group plc
https://www.mereobiopharma.comMereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor.
CEO
Denise Vera Scots-Knight
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 3
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
BTIG
Buy
Needham
Buy
JP Morgan
Overweight
Cantor Fitzgerald
Overweight
LifeSci Capital
Market Perform
Jefferies
Hold
Grade Summary
Showing Top 6 of 6
Price Target
Institutional Ownership
JANUS HENDERSON GROUP PLC
Shares:16.29M
Value:$11.67M
RUBRIC CAPITAL MANAGEMENT LP
Shares:15.31M
Value:$10.97M
FRAZIER LIFE SCIENCES MANAGEMENT, L.P.
Shares:9.44M
Value:$6.76M
Summary
Showing Top 3 of 90
About Mereo BioPharma Group plc
https://www.mereobiopharma.comMereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 ▼ | $10.01M ▼ | $-7.02M ▲ | 0% ▲ | $-0.05 ▲ | $-9.81M ▲ |
| Q2-2025 | $500K ▲ | $10.87M ▼ | $-14.62M ▼ | -2.92K% ▼ | $-0.09 ▼ | $-14.29M ▼ |
| Q1-2025 | $0 | $11.2M ▼ | $-12.89M ▼ | 0% | $-0.08 ▼ | $-12.44M ▼ |
| Q4-2024 | $0 | $14.86M ▲ | $-6.98M ▲ | 0% | $-0.04 ▲ | $-6.91M ▲ |
| Q3-2024 | $0 | $9.37M | $-15M | 0% | $-0.1 | $-14.37M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $48.7M ▼ | $53.6M ▼ | $7M ▼ | $46.6M ▼ |
| Q2-2025 | $56.13M ▼ | $62.63M ▼ | $8.45M ▲ | $54.18M ▼ |
| Q1-2025 | $62.48M ▼ | $68.32M ▼ | $8.24M ▼ | $60.08M ▼ |
| Q4-2024 | $69.8M ▼ | $76.39M ▼ | $15.42M ▼ | $60.97M ▼ |
| Q3-2024 | $80.52M | $88.75M | $16.21M | $72.54M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-7.02M ▲ | $-7.31M ▲ | $300K ▲ | $0 ▲ | $-7.43M ▼ | $-7.31M ▲ |
| Q2-2025 | $-14.62M ▼ | $-7.65M ▲ | $0 ▲ | $-134K ▼ | $-6.36M ▲ | $-7.65M ▲ |
| Q1-2025 | $-12.89M ▼ | $-8.33M ▲ | $-320K ▼ | $422K ▲ | $-7.32M ▲ | $-8.65M ▲ |
| Q4-2024 | $-7.05M ▲ | $-9.42M ▼ | $0 | $-40K ▲ | $-10.72M ▼ | $-9.42M ▼ |
| Q3-2024 | $-15M | $-7.52M | $0 | $-594K | $-6.91M | $-7.52M |
CEO
Denise Vera Scots-Knight
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 3
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
BTIG
Buy
Needham
Buy
JP Morgan
Overweight
Cantor Fitzgerald
Overweight
LifeSci Capital
Market Perform
Jefferies
Hold
Grade Summary
Showing Top 6 of 6
Price Target
Institutional Ownership
JANUS HENDERSON GROUP PLC
Shares:16.29M
Value:$11.67M
RUBRIC CAPITAL MANAGEMENT LP
Shares:15.31M
Value:$10.97M
FRAZIER LIFE SCIENCES MANAGEMENT, L.P.
Shares:9.44M
Value:$6.76M
Summary
Showing Top 3 of 90